Ocugen's Q3 revenue up 43%, OCU410ST trial progresses, $20mln raised.

• Ocugen's Phase 2/3 trial for OCU410ST expected to complete enrollment by 1H 2027. • European Medicines Agency accepts single US-based trial for Marketing Authorization Application. • Licensing agreement with Kwangdong Pharmaceutical for exclusive rights in South Korea. • Sales milestones and royalties projected for OCU400 in South Korea. • Ocugen closes $20 million registered direct offering of common stock and warrants. • Potential $30 million additional gross proceeds from warrants exercise.